Figures & data
Table I. Patients’ characteristics.
Table II. Comparison of patients transplanted with HLA class I, class I + II, or class I + II mismatched donors.
Figure 1. Cumulative incidence of II–IV and III–IV acute graft-versus-host disease (GVHD) after haploidentical transplantation. A: Comparison of the incidence of II–IV acute GVHD between patients with human leukocyte antigen (HLA)-B plus HLA-DR mismatched donors and those without (P=0.011); B: Comparison of the incidence of III–IV acute GVHD between patients with HLA-B plus HLA-DR mismatched donors and those without (P=0.015).
![Figure 1. Cumulative incidence of II–IV and III–IV acute graft-versus-host disease (GVHD) after haploidentical transplantation. A: Comparison of the incidence of II–IV acute GVHD between patients with human leukocyte antigen (HLA)-B plus HLA-DR mismatched donors and those without (P=0.011); B: Comparison of the incidence of III–IV acute GVHD between patients with HLA-B plus HLA-DR mismatched donors and those without (P=0.015).](/cms/asset/c182bad5-0059-4f8e-8ea9-39d897cf40c8/iann_a_291056_f0001_b.gif)
Table III. Clinical outcome in relation to the number of HLA mismatches.
Table IV. Characteristics of relapsed patients and outcomes.
Figure 2. Comparison of overall survival in four groups of patients defined according to the stage of disease (chronic phase (CP) 1, CP2, acute phase (AP), blast crisis (BC)). The best is patients transplanted in CP2, then patients in CP1, AP, and BC. No significant differences were found in our transplant protocol.
![Figure 2. Comparison of overall survival in four groups of patients defined according to the stage of disease (chronic phase (CP) 1, CP2, acute phase (AP), blast crisis (BC)). The best is patients transplanted in CP2, then patients in CP1, AP, and BC. No significant differences were found in our transplant protocol.](/cms/asset/56db8aa2-c669-4701-ac28-602c6ee8592f/iann_a_291056_f0002_b.gif)
Table V. Multivariate analysis: factors affecting transplantation outcome.